Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Gmbh & Co Kg

Drazen Kostelac

Bernd Liepold

Yi Gao

Thomas Kessler

Eric Allen Schmitt

Yi Shi

Nancy E Sever

Carl M Knable

Ping Gao

John B Morris

Mark Costello

Mirko Pauli

Peter Hoelig

Rajeev Gokhale

Fatih Durak

Karin Rosenblatt

Anna Moosmann

Norbert Steiger

Martin Knobloch

Claudia Packhaeuser

Susan George

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

Growing community of inventors

Mannheim, Germany

Drazen Kostelac